2025-08-21 - Analysis Report
Okay, here's the analysis of Transmedics Group Inc (TMDX) based on the provided data, presented in a concise report format:

## Transmedics Group Inc (TMDX) - Stock Analysis

**Company Overview:** Transmedics Group Inc is a medical technology company focused on developing and delivering innovative organ care system technologies.

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 225.19%
*   **VOO Cumulative Return:** 37.28%
*   **Absolute Spread:** 175.4
*   **Relative Spread:** 66.4 (Indicates TMDX is positioned in the upper range of its historical outperformance relative to VOO)

**Analysis:** TMDX has significantly outperformed the S&P 500. The relative spread suggests this outperformance is substantial compared to its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD   | Alpha   | Beta | Cap(B) |
|------------|----------|-------|---------|------|--------|
| 2019-2021  | -19.0%   | 0.0%  | -20.0%  | 0.2  | 0.7    |
| 2020-2022  | 107.0%   | 68.3% | 118.0%  | 0.0  | 2.1    |
| 2021-2023  | 124.0%   | 69.4% | 114.0%  | -0.0 | 2.7    |
| 2022-2024  | 143.0%   | 82.8% | 113.0%  | -0.0 | 2.1    |
| 2023-2025  | 116.0%   | 82.8% | 73.0%   | -0.0 | 4.2    |

**Analysis:**

*   **CAGR:**  High growth rates in recent periods (2020-2025), indicating strong performance.
*   **MDD:**  High Maximum Drawdown (MDD) values suggest significant volatility and risk.
*   **Alpha:**  Consistently high Alpha values indicate substantial outperformance relative to the market.
*   **Beta:**  Beta values ranging from near 0 to high, fluctuating risk exposure. High Beta values suggesting significant sensitivity to market movements.
*   **Cap(B):**  Increasing capitalization, reflecting growth in the company's market value.

### 2. Recent Stock Price Volatility

*   **Current Price:** 121.88
*   **Previous Close:** 122.68
*   **Change:** -0.65
*   **5-day Moving Average:** 125.5
*   **20-day Moving Average:** 119.686
*   **60-day Moving Average:** 124.4975

**Analysis:** The stock price is slightly down from the previous close. The 5-day moving average is above the 20-day and 60-day, suggesting recent upward momentum, but the current price is below all three averages, potentially indicating a short-term pullback. The negative change from the previous close, while small, contributes to this short-term downward signal.

### 3. Market Risk Indicators & Outlook

*   **Market Risk Indicator (MRI):** 0.3316 (Low Risk)
*   **RSI:** 52.84 (Neutral - neither overbought nor oversold)
*   **PPO:** 0.4322
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.33)
*   **Delta_Previous_Relative_Divergence:** -1.9 (Short-term decrease in relative outperformance)
*   **Expected Return:** 54.6% (Long-term, relative to S&P 500)

**Analysis:** The MRI indicates low market risk, while the RSI is neutral. The Hybrid Signal suggests a cautious buying opportunity. The negative delta in relative divergence suggests some recent underperformance compared to its historical trend. A high expected return indicates significant potential for long-term outperformance.
Given the negative change in price, this could be a sign of a minor issue.

### 4. Recent News & Events

*   **2025-08-18:** Business developments, regulatory changes, or market events.
*   **2025-08-20:** Analyst discussions on performance and outlook.
*   **2025-08-17:** Stock volatility influenced by recent news.
*   **2025-08-19:** Market experts highlight risks and opportunities.

**Analysis:** Recent news suggests the company is experiencing significant events that are influencing the stock price. These events require further investigation to determine their long-term impact.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 예상 EPS |
|------------|-------|----------|
| 2025-07-30 | 0.92  | 0.48     |
| 2025-05-08 | 0.7   | 0.29     |
| 2025-02-27 | 0.19  | 0.22     |
| 2024-10-28 | 0.12  | 0.29     |
| 2024-07-31 | 0.35  | 0.21     |

**Analysis:** TMDX has consistently beaten EPS expectations in recent quarters. This indicates strong financial performance and positive growth momentum. The significant outperformance in the most recent quarter (2025-07-30) is particularly noteworthy.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.16B  | 61.38%        |
| 2025-03-31 | $0.14B  | 61.47%        |
| 2024-12-31 | $0.12B  | 59.21%        |
| 2024-09-30 | $0.11B  | 55.94%        |
| 2024-06-30 | $0.11B  | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE     |
|------------|---------|---------|
| 2025-06-30 | $0.32B  | 10.97%  |
| 2025-03-31 | $0.27B  | 9.64%   |
| 2024-12-31 | $0.23B  | 3.00%   |
| 2024-09-30 | $0.21B  | 2.01%   |
| 2024-06-30 | $0.19B  | 6.42%   |

**Analysis:** Both revenue and equity are increasing over time, indicating growth. The profit margin is consistently high, suggesting efficient operations. ROE has also increased significantly, reflecting improved profitability and efficient use of equity.

### 7. Overall Analysis & Recommendation

Transmedics Group Inc (TMDX) shows strong growth potential with high returns, consistent earnings beats, and increasing revenue and profitability. However, it also exhibits high volatility and sensitivity to market movements, as evidenced by its Beta and Maximum Drawdown. The recent news and events could be catalysts for further price movements.

**Recommendation:** While the long-term outlook is positive, investors should be aware of the potential for short-term volatility. Consider the "Caution" signal and the negative Delta in relative divergence. It might be prudent to scale into a position gradually, monitoring news and market reactions.
